Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

“When scaling up a process based on adherent cells, a biopharmaceutical manufacturer has two options. Either stay in 2D, resulting in the use of heavy and difficult-to-handle multi-tray stacks with a ...

Turning silver nanoparticles into commercial products could create a faster pathway to new antimicrobials and cancer treatments.

Artificial intelligence (AI) and the Internet of Things (IoT) are about to revolutionize the biopharmaceutical industry.

The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...

A comprehensive atlas maps DNA methylation across 39 human cell types, revealing a complex landscape of epigenetic regulation.

Study findings indicate therapeutic potential of microbiome-based intervention to restore bile acid balance and promote gut healing in ulcerative colitis.

Lonza will leverage its expertise in exosome development and analytical services to define a GMP-compliant process for Exo-101 production.

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.

Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).

New research shows that mutations in DNMT3A in blood stem cells of frequent blood donors may bolster the production of noncancerous cells.